Mats Hellström

742 total citations
27 papers, 314 citations indexed

About

Mats Hellström is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mats Hellström has authored 27 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mats Hellström's work include Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (14 papers) and HER2/EGFR in Cancer Research (11 papers). Mats Hellström is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (14 papers) and HER2/EGFR in Cancer Research (11 papers). Mats Hellström collaborates with scholars based in Sweden, Germany and Austria. Mats Hellström's co-authors include Jonas Bergh, Hemming Johansson, K Pedersen, Theodoros Foukakis, Hans Wijkström, Thomas Hatschek, Christopher Büsch, Manuel de la Torre, Michael Gnant and Richard Greil and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Mats Hellström

26 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mats Hellström Sweden	12	150	130	91	57	34	27	314
Elisa Rizzo Italy	6	190 1.3×	132 1.0×	76 0.8×	47 0.8×	30 0.9×	7	343
Taryn Stoffs United States	6	208 1.4×	232 1.8×	74 0.8×	120 2.1×	36 1.1×	7	526
Gautier Paux France	9	115 0.8×	110 0.8×	50 0.5×	41 0.7×	34 1.0×	26	394
Stephen Stefani Brazil	7	86 0.6×	77 0.6×	108 1.2×	78 1.4×	8 0.2×	29	321
B. Munárriz Spain	8	236 1.6×	67 0.5×	129 1.4×	53 0.9×	10 0.3×	19	364
Sachi Morita Japan	10	167 1.1×	58 0.4×	56 0.6×	102 1.8×	14 0.4×	25	285
Jean-François Caubet United States	6	200 1.3×	255 2.0×	44 0.5×	114 2.0×	20 0.6×	8	473
H. Ballentine Carter United States	9	173 1.2×	268 2.1×	66 0.7×	123 2.2×	22 0.6×	14	544
Xuyang Song United States	9	331 2.2×	155 1.2×	62 0.7×	78 1.4×	13 0.4×	26	506
Jussi Aro Finland	11	146 1.0×	345 2.7×	41 0.5×	47 0.8×	22 0.6×	19	458

Countries citing papers authored by Mats Hellström

Since Specialization

Citations

This map shows the geographic impact of Mats Hellström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mats Hellström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mats Hellström more than expected).

Fields of papers citing papers by Mats Hellström

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mats Hellström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mats Hellström. The network helps show where Mats Hellström may publish in the future.

Co-authorship network of co-authors of Mats Hellström

This figure shows the co-authorship network connecting the top 25 collaborators of Mats Hellström. A scholar is included among the top collaborators of Mats Hellström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mats Hellström. Mats Hellström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matikas, Alexios, Bjørn Naume, Hans Wildiers, et al.. (2025). A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).. Journal of Clinical Oncology. 43(16_suppl).

Karakatsanis, Andreas, Anne Andersson, Zakaria Einbeigi, et al.. (2024). 339TiP A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE). Annals of Oncology. 35. S356–S356. 1 indexed citations

Matikas, Alexios, Andri Papakonstantinou, Sibylle Loibl, et al.. (2024). Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. The Lancet Regional Health - Europe. 49. 101162–101162. 2 indexed citations

Zerdes, Ioannis, Alexios Matikas, Mattias Bergqvist, et al.. (2024). The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial. Breast Cancer Research and Treatment. 204(2). 299–308. 2 indexed citations

Mercke, Claes, Gun Wickart-Johansson, Helena Sjödin, et al.. (2023). Radiotherapy—Dose Escalated for Large Volume Primary Tumors—And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck—A Randomized Phase II Trial. Cancers. 15(9). 2543–2543. 1 indexed citations

Brandberg, Yvonne, Hemming Johansson, Mats Hellström, et al.. (2020). Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. Breast Cancer Research and Treatment. 181(1). 87–96. 9 indexed citations

Hatschek, Thomas, Anne Andersson, Judith Bjöhle, et al.. (2020). 97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels. Annals of Oncology. 31. S49–S49. 4 indexed citations

Jensen, Niels Viggo, Mads Agerbæk, Cecilia Nilsson, et al.. (2019). Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). European Journal of Cancer. 127. 173–182. 16 indexed citations

Papakonstantinou, Andri, Alexios Matikas, Per Malmström, et al.. (2019). Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Cancer. 126(6). 1175–1182. 14 indexed citations

10.

Bergh, Jonas, Anne Andersson, Judith Bjöhle, et al.. (2019). Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?. Journal of Clinical Oncology. 37(15_suppl). 501–501. 16 indexed citations

11.

Matikas, Alexios, Theodoros Foukakis, Volker Moebus, et al.. (2018). Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. Annals of Oncology. 30(1). 109–114. 17 indexed citations

12.

Matikas, Alexios, Sara Margolin, Mats Hellström, et al.. (2017). Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment. 168(2). 349–355. 7 indexed citations

13.

Brandberg, Yvonne, Hemming Johansson, Mats Hellström, et al.. (2016). The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel—Health-related quality of life during ongoing therapy.. Journal of Clinical Oncology. 34(15_suppl). 1035–1035. 2 indexed citations

14.

Hatschek, Thomas, Lena Carlsson, Zakaria Einbeigi, et al.. (2011). Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Research and Treatment. 131(3). 939–947. 23 indexed citations

15.

Margolin, Sara, Nils‐Olof Bengtsson, Lena Carlsson, et al.. (2010). A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncologica. 50(1). 35–41. 15 indexed citations

16.

Kuchinke, Wolfgang, Christian Ohmann, Qin Yang, et al.. (2010). Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. Trials. 11(1). 79–79. 41 indexed citations

17.

Hellström, Mats, et al.. (1997). Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. British Journal of Urology. 79(3). 421–426. 14 indexed citations

18.

Hellström, Mats, et al.. (1996). A 3‐year follow‐up of patients with localized prostate cancer operated on with or without pre‐treatment with the GnRH‐agonist triptorelin. British Journal of Urology. 78(3). 432–436. 8 indexed citations

19.

Hellström, Mats, et al.. (1993). Histopathological Changes inAndrogen-Deprived LocalizedProstatic Cancer. European Urology. 24(4). 461–465. 44 indexed citations

20.

Pedersen, K, Hans Wijkström, Reinhard Stege, et al.. (1993). Neoadjuvant GnRH-AgonistTreatment (Triptorelin andCyproterone Acetatefor Flare Protection) andTotal Prostatectomy. European Urology. 24(4). 456–460. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact